Burns: Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?

Short Title:
Model System:
Burn
Reference Type:
Journal Article
Accession No.:
J62905
Journal:
Current Opinion in Clinical Nutrition and Metabolic Care
Year, Volume, Issue, Page(s):
2011, vol. 14, issue 2, pp 176-181
Publication Website:
Abstract:
This review article discusses the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic, and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-gamma agonists are under current investigation.
Author(s):
Gaulglitz G.G.; Williams F.N.; Herndon D.N.; Jeschke M.G.
Author Address(es):

Some items may be available for document delivery from the National Rehabilitation Information Center. Make a note of the title and any accession number and contact NARIC at 800-346-2742 to request a copy. There is a charge for document delivery from the NARIC collection.